<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314546</url>
  </required_header>
  <id_info>
    <org_study_id>994</org_study_id>
    <nct_id>NCT02314546</nct_id>
  </id_info>
  <brief_title>Intranasal Midazolam in Children as a Pre-Operative Sedative</brief_title>
  <official_title>Intranasal Midazolam in Children as a Pre-Operative Sedative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if adding a numbing medicine, xylocaine, to the nasal
      midazolam makes giving the midazolam easier and more comfortable without affecting how the
      midazolam works as a sedative.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Midazolam is often given before surgery to sedate a patient before anesthesia is given.
      Children are often given a small dose either by mouth or squirted into the nose. Children
      will often spit out the oral midazolam, making it difficult to know how much medicine, if
      any, they have received. Giving midazolam into the nose is more reliable, but children may
      complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also
      occur when midazolam is squirted alone into the nose. The purpose of this study is to see if
      adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam
      easier and more comfortable without affecting how the midazolam works as a sedative.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation Scale Score</measure>
    <time_frame>10 minutes post-sedation</time_frame>
    <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation Scale Score</measure>
    <time_frame>15 minutes post-sedation</time_frame>
    <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time From Administration to Discharge</measure>
    <time_frame>Minutes from administration to discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parental Observed Behavioral Distress Score</measure>
    <time_frame>1 minute post-administration</time_frame>
    <description>Measured by the accompanying parent using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RN Observed Behavioral Distress Score</measure>
    <time_frame>1 minute post-administration</time_frame>
    <description>Measured by the administering RN using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Complaint</measure>
    <time_frame>At time of administration</time_frame>
    <description>Recorded by the administering RN at the time of administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Complaints</measure>
    <time_frame>1 minute post-administration</time_frame>
    <description>Recorded by the administering RN at one minute post-administration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Sedation, Conscious</condition>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Midazolam only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam and Xylocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Study participants will be randomly assigned to one of three treatment groups:
Group 1 - Placebo - Control patients will receive intranasal saline.
Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
    <arm_group_label>Nasal Midazolam only</arm_group_label>
    <arm_group_label>Midazolam and Xylocaine</arm_group_label>
    <other_name>versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xylocaine</intervention_name>
    <description>Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
    <arm_group_label>Midazolam and Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline placebo</intervention_name>
    <description>Placebo - Control patients will receive intranasal saline.</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged 18 months-7 years, scheduled for a minor otolaryngology (ENT) surgical
             procedure requiring mask anesthesia

          2. American Society of Anesthesiologists (ASA) Class 1 or 2

          3. Parent willing and able to provide written informed consent

          4. Parent willing and able to complete the OBD VAS

        Exclusion Criteria:

          1. ASA Class 3 or greater

          2. History of allergy to midazolam or xylocaine

          3. Presence of acute respiratory infection at time of surgery

          4. Parent unwilling or unable to provide informed consent

          5. Parent unwilling or unable to complete the OBD VAS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>david Ullman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bassett Healthcare Network</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <results_first_submitted>January 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>David A Ullman MD</investigator_full_name>
    <investigator_title>Attending Physician - Anesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Placebo</title>
          <description>Control patients received intranasal saline.</description>
        </group>
        <group group_id="P2">
          <title>Nasal Midazolam Only</title>
          <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
        </group>
        <group group_id="P3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>It was determined that a minimum of 15 patients (5 in each group) were necessary for baseline statistical analysis of this pilot study, to be used in performing a formal power analysis and sample size calculation. However, limitations in the number of providers and eligible patients during the two-year study period prevented further recruitment.</population>
      <group_list>
        <group group_id="B1">
          <title>Saline Placebo</title>
          <description>Control patients received intranasal saline.</description>
        </group>
        <group group_id="B2">
          <title>Nasal Midazolam Only</title>
          <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
        </group>
        <group group_id="B3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="2.2"/>
                    <measurement group_id="B2" value="4.0" spread="1.2"/>
                    <measurement group_id="B3" value="4.0" spread="2.0"/>
                    <measurement group_id="B4" value="3.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists Physical Status Class</title>
          <description>ASA Class 1: A healthy patient, ASA Class 2: A patient with mild systemic disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA Class 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sedation Scale Score</title>
        <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
        <time_frame>10 minutes post-sedation</time_frame>
        <population>participants with available data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Scale Score</title>
          <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
          <population>participants with available data at this time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agitated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alert</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sedation Scale Score</title>
        <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
        <time_frame>15 minutes post-sedation</time_frame>
        <population>participants with available data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Scale Score</title>
          <description>Measured by the administering RN. Measured as: agitated, alert, calm, drowsy, asleep.</description>
          <population>participants with available data at this time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agitated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alert</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time From Administration to Discharge</title>
        <time_frame>Minutes from administration to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Administration to Discharge</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" spread="21.9"/>
                    <measurement group_id="O2" value="74.2" spread="9.6"/>
                    <measurement group_id="O3" value="97.0" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parental Observed Behavioral Distress Score</title>
        <description>Measured by the accompanying parent using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
        <time_frame>1 minute post-administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Parental Observed Behavioral Distress Score</title>
          <description>Measured by the accompanying parent using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.2"/>
                    <measurement group_id="O2" value="3.10" spread="2.4"/>
                    <measurement group_id="O3" value="1.96" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RN Observed Behavioral Distress Score</title>
        <description>Measured by the administering RN using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
        <time_frame>1 minute post-administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>RN Observed Behavioral Distress Score</title>
          <description>Measured by the administering RN using a Visual Analog Scale. The scale ranges from a minimum score of 0 (no distress at all) to a maximum of 10 (most distress possible).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="2.4" spread="3.0"/>
                    <measurement group_id="O3" value="1.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal Complaint</title>
        <description>Recorded by the administering RN at the time of administration.</description>
        <time_frame>At time of administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Complaint</title>
          <description>Recorded by the administering RN at the time of administration.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Complaint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complaint Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal Complaints</title>
        <description>Recorded by the administering RN at one minute post-administration</description>
        <time_frame>1 minute post-administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients received intranasal saline.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Complaints</title>
          <description>Recorded by the administering RN at one minute post-administration</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Complaint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complaint Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During hospital stay.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline Placebo</title>
          <description>Control patients received intranasal saline.</description>
        </group>
        <group group_id="E2">
          <title>Nasal Midazolam Only</title>
          <description>Patients received 0.2 mg/kg of intranasal midazolam</description>
        </group>
        <group group_id="E3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations in the number of providers and eligible patients during the two-year study period.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David A. Ullman, MD, Senior Attending Anesthesiologist</name_or_title>
      <organization>Bassett Healthcare Network</organization>
      <phone>607-547-3153</phone>
      <email>david.ullman@bassett.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

